Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMRN | Amarin Corp. Plc | 23.83% | 20.94 | 1.7% | $162.94m | |
| VRX | Valeant Pharmaceuticals International, Inc. | 1.85% | 27.01 | 14.1% | $158.93m | |
| BHC | Bausch Health Cos., Inc. | 1.85% | 27.01 | 0.0% | $119.66m | |
| GWPH | GW Pharmaceuticals Plc | -3.38% | 109.40 | 6.2% | $81.05m | |
| MDCO | The Medicines Co. | -3.58% | 53.39 | 20.2% | $78.63m | |
| JAZZ | Jazz Pharmaceuticals Plc | 1.11% | 132.33 | 2.3% | $69.12m | |
| SAGE | SAGE Therapeutics, Inc. | -1.93% | 141.55 | 8.6% | $52.41m | |
| PRGO | Perrigo Co. Plc | -1.67% | 48.28 | 6.8% | $46.00m | |
| ENDP | Endo International Plc | 0.61% | 4.14 | 8.8% | $44.46m | |
| HZNP | Horizon Therapeutics Plc | 0.73% | 30.23 | 6.6% | $40.27m | |
| UTHR | United Therapeutics Corp. | -1.53% | 89.57 | 14.3% | $39.81m | |
| ICPT | Intercept Pharmaceuticals, Inc. | 1.29% | 83.02 | 16.9% | $39.56m | |
| ICLR | ICON plc | 0.73% | 147.24 | 4.1% | $37.50m | |
| CTLT | Catalent, Inc. | -0.74% | 49.48 | 2.4% | $32.17m | |
| AERI | Aerie Pharmaceuticals, Inc. | -0.89% | 18.88 | 6.8% | $26.95m |
Company Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.